Use of Real-World Claim Databases to Assess Prevalence of Comorbid Conditions Relevant to the Treatment of Chronic Myelogenous Leukemia Based on National Comprehensive Network Treatment Guidelines

Conclusions The results of this analysis provide real-world evidence that the prevalence of relevant comorbid conditions is substantial among CML patients in the U.S. managed care setting and therefore, needs to be considered throughout various healthcare decision making processes related to CML. Teaser This study assessed the prevalence of comorbid conditions relevant to TKI treatment choice per NCCN guidelines among CML patients in the U.S. real-world setting. The results of the analysis provide real-world evidence that the prevalence of relevant comorbid conditions is substantial among CML patients and therefore, needs to be considered throughout various healthcare decision making processes related to CML.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research